Fortress Biotech (FBIO) Investor Presentation - Slideshow

• ASCO 2022 presentation of top-line data in metastatic cSCC (n=78) showed a confirmed objective response rate (ORR) by independent central review in the modified intent to treat population of 48.7% and 13.2% of patients achieving a complete response in target lesions. • Composition of Matter patent issued in US, expiring no earlier than 2038 13 Est. Market Next Steps Expected to complete rolling submission of NDA in 2023^ CUTX-101 • Reported positive top-line clinical efficacy data, showing a nearly 80% re ...